

FINEVISION HP Trifocal Hydrophobic IOL


THE STAR TREATMENT





bvimedical.com

FINEVISION HP & HP TORIC the evolution of the original FINE trifocal technology that reduce the burden of spectacle, offering continuous vision to accomplish any task at all distances¹ with the advantages of the GFY hydrophobic raw material.




^(:) What patients say ?

Do you still depend on glasses after FINEVISION treatment? (n=5,802 patients)

100% 80% 95% of patients reach 60% Datients complete spectacle 99% 98% 95% 40% 97% of patients treated with 20% FINEVISION would choose 0% Intermediate Near the same IOL again!¹ Distance


CoPODize[™] technology

The first and only optic that uses CoPODize technology, that combines both Convolution and Apodization concepts on the entire optic surface. This unique technology is optimized to work in harmony with the pupil - managing the risk of halo and glare when transitioning to mesopic conditions.



\bigotimes Hydrophobic raw material (GFY)

The IOL must withstand the test of time for the life of the patient. Glistenings have been a known phenomena for hydrophobic IOLs, forming over time following implantation, which can impact the quality of vision.³ GFY hydrophobic material is unique to BVI. Accelerated age testing at David J. Apple Laboratory demonstrated that GFY material is glistening free. ^{4,5,6}



Simulation of the accelerated ageing in vitro glistening formation⁷



GFY hydrophobic material



Over a million GFY IOLs have been implanted since it first use in 2010 and a clinical study⁹ showed no glistenings after a 3 year follow-up. Within this publication, a

Hydrophobic raw material

rate of 2.3% of YAG capsulotomy was recorded over a 3 years period.

(:) What are the patient's benefits


The GFY raw material is a Grade 0 based on the Miyata glistening scale (in vitro)^{4, 5, 6}

No significant difference in microvacuoles formation was observed with the GFY material compared to the hydrophilic reference material (in vitro).⁸


"The GFY material showed its effectiveness in the absence of glistening. This survival analysis shows no glistening event during 36 months follow-up."⁹



"One YAG has been made in the GFY IOL cohort after the third year (n = 43 eyes)."⁹



\bigstar Give every patient's eyes the star treatment



POD haptic platform has 70% greater contact angle vs C-loop IOL platform¹²

POD platform with

capsular bag junction¹⁰

Maintain low tilt and axial displacement¹¹

• Provide excellent centration and rotation stability¹¹



of experience with IOLs, providing reliability in terms of clinical outcomes¹³ POD L GF - Absolute postoperative IOL axis rotation (°) at 4-6 months compared to the day of surgery.¹⁴

BVI toric calculator has been developed to account the posterior corneal curvature by creating an indirect benefits on the postoperative astigmatic patient outcomes.¹⁵

Go to Physioltoric.eu

© "Easy control during the procedure"¹⁶

🚫 Unique haptic design for **Toric** version

conventional C-loop designs. This platform is designed to:

POD platform is designed with a unique double C-loop haptics configuration for excellent fixation within the capsular bag, with an increased contact angle¹² as well as 4-point contact versus


• Allow for even distribution of the compression forces at the haptic-

(Classic C-loop can only rotate clockwise)

Easy placement is MANEUVERABILITY Rotation to align the IOL cylinder, either clockwise OR counter-clockwise reducing the risk of misalignment.

Unique *RidgeTech technology* reduces the risk¹⁷ of sticky haptics on the optics during and after injection.






Medicel Accuject injector guidelines with POD platform

This fully single-use system represents reliable and effective lens injections with POD platform. Their compact design with integrated cartridge enables predictable loading and positioning of the lens.

Guidelines steps with Accuject:



- 1. Apply ophthalmic viscoelastic device (OVD) into the tip and the loading chamber of the injector cartridge.
- 2. Remove the lens from the lens holder. Position the lens into the cartridge in such way that the two haptics with the notches are pointing at 1 and 7 o'clock.
- 3. Exert slight pressure onto the lens optic and make sure that all haptics are inside before further closing the cartridge. Close the cartridge and check the position of the lens.
- 4. Once the "click-lock" mechanism engages, the lens is securely loaded and ready for injection.
- 5. Press the injector plunger forward and push the lens into the conical tip of the cartridge.
- 6. Pull the plunger back a few millimeters and then inject the lens in one continuous motion. For gentle implantation, it is not necessary to fully push the plunger to the bottom of the cartridge.

¹ R. Bilbao-Calabuig, MD et al.: Visual outcomes following bilateral implantation of two diffractive trifocal intraocular lenses in 10,084 eyes, American Journal of Ophthalmology, July 2017. | ² MDR CER Report: RA_302_1_2021_144 Clinical Evaluation | ³ E. DeHoog, PhD, A. Doraiswamy, PhD: Evaluation of the impact of light scatter from glistenings in pseudophakic eyes, J Cataract Refract Surg 2014; 40:95–103. | ⁴ Miyata A, Jpn J Ophthalmol 2001, 45(6):564-569. | ⁵ https://www.eurotimes.org/capsular-bag-stability-findl | ⁶ CER F2 (MIC-GFY) | RD-REP-210-1-2021 | V1.0 | 27.04.2021 | ⁷ Biomaterial Optical Purity. The David J Apple International Laboratory for Ocular Pathology, 3 MAY 2017 | ⁸ Biomaterial Optical Purity Report & Appendix 1, G.U. Auffarth, University Hospital Heidelberg, May 2017. | ⁶ C. Chassain, France Journal of Ophthalmology (2018) 41, 513—520 | ¹⁰ POD T 49P mechanical properties 11979-3 (RD-REP-19-09Sv02). | ¹¹ Draschl P, J Cataract Refract Surg 2017, 43(2):234-238. | ¹² Mechanical properties according to 11979-3 of Double C Loop (ID: 9988EB20-C5D6-418E-A4DA-348E1114C396) | ¹³ Periodic Clinical Evaluation Report | ¹⁴ Clinical Evaluation Report POD-GFY, Family 1 ID: 287C9C9A-A937-4CC3-AC3F-06FE3D432663 | ¹⁵ Abulafia A, Koch DD, J Cataract Refract Surg 2016, 42(5):663-671. | ¹⁶ Philipp J Ophthalmol 2014;39:67-72 | ¹⁷ Physiol Report 002, 9 nov 2012.

FINEVISION HP & HP TORIC

Description FINEVISION HP

Model		POD F GF					
Material	GFY Hydrophobic Acrylic ¹⁸						
Overall diameter	11.40mm						
Optic diameter	6.00mm						
Optic	Biconvex Aspheric Trifocal						
Haptic design	POD (Double-C-loop) with Ridgetech® & Posterior Angulated Haptic						
Filtration	UV & Blue Light						
Refractive index	1.53						
Abbe number	42						
Additional power (IOL plane)	+1.75D & +3.50D						
Injection system	Medicel Accuject 2.0 up to 24.5D - Medicel Accuject 2.1/2.2 up to 35D						
Spherical power	+10D to +35D (0.5D steps)						
		Interferometry					
	Hoffer Q: pACD	5.85					
Suggested A constant ¹⁹	Holladay 1: Sf	2.06					
A constant?	Barrett: LF	2.09					
	SRK/T: A	119.40					
	Haigis²⁰: a0; a1; a2	1.70; 0.4; 0.1					

¹⁸ The PhysIOL GFY® is patented since 2010. Patent number: EP1830898. | ¹⁹ Values estimated only: surgeons are recommended to personalize their A-constant based on their surgical techniques and equipment, experience with the lens model and postoperative results. | ²⁰ Not optimized.

Description FINEVISION HP TORIC

Model	POD FT 49P									
Material	GFY Hydrophobic Acrylic ¹⁸									
Overall diameter	11.40mm									
Optic diameter	6.00mm									
Optic	Biconvex Aspheric Toric Trifocal									
Haptic design	POD (Double-C-loop) with Ridgetech® & Posterior Angulated Haptic									
Filtration	UV & Blue Light									
Refractive index	1.53									
Abbe number	42									
Additional power (IOL plane)	+1.75D & +3.50D									
Injection system	Medicel Accuject 2.1/2.2									
Spherical power	+10D to +35D (0.5D steps)									
Cylinder power (IOL plane) ²¹	1.00 - 1.50 - 2.25 - 3.00 - 3.75 - 4.50 - 5.25 - 6.00D									
Suggested A constant ¹⁹				Interferometry						
	Hoffer Q: pACD			5.85						
	Holladay 1: Sf			2.06						
	Barrett: LF			2.09						
	SRK/T: A			119.40						
		Haigis ²⁰ : a	0; a1; a2	1.70; 0.4; 0.1						
	POD FT 49P 1.0	POD FT 49P 1.5	POD FT 49P 2	.25 POD FT 49P 3.0	POD FT 49P 3.75	POD FT 49P 4.5	POD FT 49P 5.25	POD FT 49P 6.0		
Cylinder power at IOL plane	1.00D	1.50D	2.25D	3.00D	3.75D	4.50D	5.25D	6.00D		
Cylinder power at corneal plane ²²	0.68D	1.03D	1.55D	2.06D	2.57D	3.08D	3.60D	4.11D		

¹⁸ The PhysIOL GFY[®] is patented since 2010. Patent number: EP1830898. | ¹⁹ Values estimated only: surgeons are recommended to personalize their A-constant based on their surgical techniques and equipment, experience with the lens model and postoperative results. | ²⁰ Not optimized. | ²¹ Please read the directions for Use for important safety information and consult our specialists on the spherical and cylinder powers availability. | ²² Savini G., J Cataract Refract Surg 2013; 39:1900–1903.

Please check the availability of the products on your market with your sales representative.

Contact Information: www.bvimedical.com/customer-support/ Manufacturer: PhysIOL s.a. - Liège Science Park - Allée des Noisetiers 4 - B-4031 - Belgium +32 4 361 05 49 - physiol@bvimedical.com Content last reviewed 02/2020

